Treatment response biomarkers in early Alzheimers disease: longitudinal trajectories, sample size estimates, and the impact of progression variability

Abstract

BackgroundFluid biomarkers enable the demonstration of the biological effects of novel therapies in Alzheimers disease (AD). However, longitudinal biomarker data are sparse and sample size calculations for fluid biomarkers are often lacking.

The paper